Martin Brenoe
Stock Analyst at Nordea Markets
(0.60)
# 4,212
Out of 4,659 analysts
11
Total ratings
33.3%
Success rate
-15.7%
Average return
Main Sectors:
Stocks Rated by Martin Brenoe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: 0QIU Novo Nordisk A/S | Upgraded: Buy | kr 350.00 | kr 293.50 | +19.25% | 1 | Jun 19, 2026 | |
| ZLDPF Zealand Pharma A/S | Downgraded: Hold | n/a | $49.07 | - | 1 | Mar 6, 2026 | |
| NVO Novo Nordisk | Downgraded: Hold | n/a | $44.88 | - | 1 | Feb 24, 2026 | |
| WILLF Demant A/S | Upgraded: Buy | $51 → $36 | $45.00 | -20.83% | 3 | Feb 18, 2026 | |
| LON: 0NQC Pandora A/S | Upgraded: Buy | kr 300.00 → kr 1,200 | kr 822.40 | n/a | 3 | May 7, 2025 | |
| OSSFF Embla Medical hf. | Initiated Coverage: Buy | $5.85 | $4.15 | n/a | 1 | Jun 22, 2023 | |
| PNDRY Pandora A/S | Upgraded: Hold | n/a | $15.80 | n/a | 1 | Feb 9, 2023 |
Novo Nordisk A/S
Jun 19, 2026
Upgraded: Buy
Price Target: kr 350.00
Current: kr 293.50
Upside: +19.25%
Zealand Pharma A/S
Mar 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $49.07
Upside: -
Novo Nordisk
Feb 24, 2026
Downgraded: Hold
Price Target: n/a
Current: $44.88
Upside: -
Demant A/S
Feb 18, 2026
Upgraded: Buy
Price Target: $51 → $36
Current: $45.00
Upside: -20.83%
Pandora A/S
May 7, 2025
Upgraded: Buy
Price Target: kr 300.00 → kr 1,200
Current: kr 822.40
Upside: n/a
Embla Medical hf.
Jun 22, 2023
Initiated Coverage: Buy
Price Target: $5.85
Current: $4.15
Upside: n/a
Pandora A/S
Feb 9, 2023
Upgraded: Hold
Price Target: n/a
Current: $15.80
Upside: n/a